162 related articles for article (PubMed ID: 34853037)
21. Integrated genome and tissue engineering enables screening of cancer vulnerabilities in physiologically relevant perfusable ex vivo cultures.
Hu M; Lei XY; Larson JD; McAlonis M; Ford K; McDonald D; Mach K; Rusert JM; Wechsler-Reya RJ; Mali P
Biomaterials; 2022 Jan; 280():121276. PubMed ID: 34890975
[TBL] [Abstract][Full Text] [Related]
22. Emerging Opportunities for Target Discovery in Rare Cancers.
Sharifnia T; Hong AL; Painter CA; Boehm JS
Cell Chem Biol; 2017 Sep; 24(9):1075-1091. PubMed ID: 28938087
[TBL] [Abstract][Full Text] [Related]
23. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
Potts MA; McDonald JA; Sutherland KD; Herold MJ
Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
[TBL] [Abstract][Full Text] [Related]
24. Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets.
Dwane L; Behan FM; Gonçalves E; Lightfoot H; Yang W; van der Meer D; Shepherd R; Pignatelli M; Iorio F; Garnett MJ
Nucleic Acids Res; 2021 Jan; 49(D1):D1365-D1372. PubMed ID: 33068406
[TBL] [Abstract][Full Text] [Related]
25. CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries.
Sreedurgalakshmi K; Srikar R; Rajkumari R
Cancer Gene Ther; 2021 Jun; 28(6):566-580. PubMed ID: 33191402
[TBL] [Abstract][Full Text] [Related]
26. Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway.
Chai AWY; Yee PS; Price S; Yee SM; Lee HM; Tiong VK; Gonçalves E; Behan FM; Bateson J; Gilbert J; Tan AC; McDermott U; Garnett MJ; Cheong SC
Elife; 2020 Sep; 9():. PubMed ID: 32990596
[TBL] [Abstract][Full Text] [Related]
27. Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens.
Yim S; Hwang W; Han N; Lee D
Front Immunol; 2022; 13():884561. PubMed ID: 35651625
[TBL] [Abstract][Full Text] [Related]
28. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic targeting of chromatin: status and opportunities.
Siklos M; Kubicek S
FEBS J; 2022 Mar; 289(5):1276-1301. PubMed ID: 33982887
[TBL] [Abstract][Full Text] [Related]
30. Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens.
Gonçalves E; Segura-Cabrera A; Pacini C; Picco G; Behan FM; Jaaks P; Coker EA; van der Meer D; Barthorpe A; Lightfoot H; Mironenko T; Beck A; Richardson L; Yang W; Lleshi E; Hall J; Tolley C; Hall C; Mali I; Thomas F; Morris J; Leach AR; Lynch JT; Sidders B; Crafter C; Iorio F; Fawell S; Garnett MJ
Mol Syst Biol; 2020 Jul; 16(7):e9405. PubMed ID: 32627965
[TBL] [Abstract][Full Text] [Related]
31. Development of drug-inducible CRISPR-Cas9 systems for large-scale functional screening.
Sun N; Petiwala S; Wang R; Lu C; Hu M; Ghosh S; Hao Y; Miller CP; Chung N
BMC Genomics; 2019 Mar; 20(1):225. PubMed ID: 30890156
[TBL] [Abstract][Full Text] [Related]
32. Defining a Cancer Dependency Map.
Tsherniak A; Vazquez F; Montgomery PG; Weir BA; Kryukov G; Cowley GS; Gill S; Harrington WF; Pantel S; Krill-Burger JM; Meyers RM; Ali L; Goodale A; Lee Y; Jiang G; Hsiao J; Gerath WFJ; Howell S; Merkel E; Ghandi M; Garraway LA; Root DE; Golub TR; Boehm JS; Hahn WC
Cell; 2017 Jul; 170(3):564-576.e16. PubMed ID: 28753430
[TBL] [Abstract][Full Text] [Related]
33. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
34. CRISPR therapeutic tools for complex genetic disorders and cancer (Review).
Baliou S; Adamaki M; Kyriakopoulos AM; Spandidos DA; Panayiotidis M; Christodoulou I; Zoumpourlis V
Int J Oncol; 2018 Aug; 53(2):443-468. PubMed ID: 29901119
[TBL] [Abstract][Full Text] [Related]
35. Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.
Zhu Z; Ihle NT; Rejto PA; Zarrinkar PP
BMC Genomics; 2016 Jun; 17():455. PubMed ID: 27296290
[TBL] [Abstract][Full Text] [Related]
36. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains.
Shi J; Wang E; Milazzo JP; Wang Z; Kinney JB; Vakoc CR
Nat Biotechnol; 2015 Jun; 33(6):661-7. PubMed ID: 25961408
[TBL] [Abstract][Full Text] [Related]
37. CoRe: a robustly benchmarked R package for identifying core-fitness genes in genome-wide pooled CRISPR-Cas9 screens.
Vinceti A; Karakoc E; Pacini C; Perron U; De Lucia RR; Garnett MJ; Iorio F
BMC Genomics; 2021 Nov; 22(1):828. PubMed ID: 34789150
[TBL] [Abstract][Full Text] [Related]
38. CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer.
Gao S; Soares F; Wang S; Wong CC; Chen H; Yang Z; Liu W; Go MYY; Ahmed M; Zeng Y; O'Brien CA; Sung JJY; He HH; Yu J
Oncogene; 2021 Dec; 40(48):6601-6613. PubMed ID: 34621019
[TBL] [Abstract][Full Text] [Related]
39. CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.
Naert T; Tulkens D; Van Nieuwenhuysen T; Przybyl J; Demuynck S; van de Rijn M; Al-Jazrawe M; Alman BA; Coucke PJ; De Leeneer K; Vanhove C; Savvides SN; Creytens D; Vleminckx K
Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34789568
[TBL] [Abstract][Full Text] [Related]
40. Toward an integrated map of genetic interactions in cancer cells.
Rauscher B; Heigwer F; Henkel L; Hielscher T; Voloshanenko O; Boutros M
Mol Syst Biol; 2018 Feb; 14(2):e7656. PubMed ID: 29467179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
